Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Insulin receptor" patented technology

The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of tyrosine kinase receptors. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis, a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

De novo designed protein binders and modulators of the insulin receptor

PCT designated stageWO2026075904A1Antibody mimetics/scaffoldsMetabolism disorderPancreatic hormoneInsulin receptor
Polypeptides are disclosed having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from SEQ ID NO: 1-28, not including any amino acid insertions at identified insertion sites, wherein the polypeptide binds to the F 1 domain of insulin receptor; or SEQ ID NO: 29-31, wherein the polypeptide binds to the LI domain of insulin receptor; fusion proteins thereof, and. methods for their use.
Owner:UNIV OF WASHINGTON +2

Insulin derivatives

Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The novel insulin derivatives have D-histidine or glycine at position B24, the B chain has glycine at the C-terminus at position B31 and tyrosine at position B32, and glutamic or aspartic acid at position B10. The derivatives of the invention can be used particularly for growth and proliferation stimulation in cell cultures or for treatment of neurological disorders as of Alzheimer's disease, Huntington's and Parkinson's diseases, a cognitive loss or symptoms of syndromic autism, since one derivative could mediate both insulin and IGF-1 function.
Owner:USTAV ORGANICKE CHEM A BIOCHEM AKADE VED CR V V I

A uorf element for regulating expression of chicken insulin receptor and application thereof

ActiveCN120796258BEucaryotic cellLow insulin
The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Application of glycerol monodecanoate in preparation of hypoglycemic drug or functional food

Disclosed is an application of glycerol monodecanoate (GMD) in the preparation of a hypoglycemic drug or a functional food, falling within the technical field of medicine. According to the present disclosure, the hypoglycemic and insulin resistance-improving functions of GMD are first revealed. Studies demonstrate that GMD can enhance glucagon-like peptide-1 (GLP-1) secretion, activate hepatic glycolysis and insulin receptor (INSR)-related gene expression, while inhibiting hepatic gluconeogenesis pathway-related gene expression. Notably in type 2 diabetes mellitus (T2DM), glucose-lowering efficacy of GMD is comparable to metformin, and it outperforms metformin in regulating glucose tolerance and insulin tolerance, with significant alleviation of polydipsia. Moreover, as GMD is a naturally occurring edible substance with a high safety profile, it has a good application prospect in the preparation of a drug for treating hyperglycemia and diabetes, or a functional food to assist in lowering blood glucose.
Owner:HANGZHOU KANGYUAN FOOD SCI & TECH +1